Compare AbbVie Inc (ABBV) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while iShares 20 Plus Year Treasury Bond ETF trades at $84.31. The key difference: AbbVie Inc pays a 2.72% dividend while iShares 20 Plus Year Treasury Bond ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | TLT | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $92.06 |
52-Week Low | $184.85 | $83.02 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates solid revenue growth, reaching $61.16B in 2025, though net margins have compressed to 5.79%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $2.65 exceeding the $2.59 forecast. Positive clinical trial results for ELAHERE in ovarian cancer and institutional buying activity support investor confidence.
AbbVie presents a favorable risk-reward profile with 68% analyst buy ratings and a $266.33 consensus price target offering 5.4% upside. Key opportunities include Skyrizi/Rinvoq growth offsetting Humira declines, while risks involve patent expirations in the 2030s and margin pressure. The stock's elevated P/E of 124.83 reflects growth expectations but warrants monitoring of execution against guidance.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $84.55, down 1.12% on the day, reflecting ongoing bearish pressure in the long-duration Treasury market. Technical indicators are predominantly bearish, with moving averages signaling a strong sell, while oscillators remain neutral. The fund has faced significant drawdowns recently, losing nearly 48% since 2020, but now offers higher starting yields, attracting investor attention amid shifting Fed policy expectations and inflation concerns.
The outlook for TLT hinges on Federal Reserve interest rate decisions and inflation trends. Opportunities exist for yield-seeking investors due to elevated distributions, but risks include potential further rate hikes, prolonged high inflation, and interest rate sensitivity. Market sentiment is mixed, with some analysts seeing value after the steep decline, while others caution about duration risk in a volatile macroeconomic environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
